Zimmer Biomet (ZBH)
(Delayed Data from NYSE)
$111.29 USD
+0.65 (0.59%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $111.30 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$111.29 USD
+0.65 (0.59%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $111.30 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
Zacks News
Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. With operations in over 25 countries, Zimmer markets products in more than 100 countries. In 2015, Zimmer Holdings, Inc. (the legacy company) acquired Biomet, Inc. to form a new consolidated company.
Thermo Fisher (TMO) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
With vaccine rollouts through Q2, Thermo Fisher's (TMO) Life-Science Solutions segment is likely to have registered top-line contributions from vaccine and therapy production supplies.
Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
4 Safe MedTech Bets Before Delta Strain Disrupts the Market Again
by Urmimala Biswas
Here are four MedTech stocks, HSIC, BRBR, MRVI and EYE, with favorable Zacks Rank and stellar growth parameters.
5 MedTech Stocks to Gain in 2021 as Base Business Recovers
by Urmimala Biswas
These five MedTech stocks, EYE, MRVI, SONVY, SARTF and HSIC, all with a favorable Zacks Rank and growth parameters are expected to put up a robust performance in 2021.
Zimmer Biomet (ZBH) Witnesses Post-Pandemic Business Revival
by Zacks Equity Research
Zimmer Biomet's (ZBH) spin-off decision of the non-core dental and spine business is expected to prove strategic.
Zimmer (ZBH) Down 7.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold On to Zimmer Biomet (ZBH) Stock Now
by Zacks Equity Research
Investors are optimistic about Zimmer Biomet (ZBH) on solid first-quarter results and a gradually stabilizing global musculoskeletal market.
Zimmer Biomet's (ZBH) Recovery to Continue Despite Pandemic
by Zacks Equity Research
Zimmer Biomet's (ZBH) spin-off decision of the non-core dental and spine business is expected to prove strategic.
Zimmer Biomet (ZBH) Q1 Earnings Top, Operating Margin Up
by Zacks Equity Research
Zimmer Biomet's (ZBH) core hip and S.E.T. business registers growth in the reported quarter.
Zimmer Biomet (ZBH) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Zimmer (ZBH) delivered earnings and revenue surprises of 13.25% and 5.94%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
BD (BDX) Gears Up for Q2 Earnings: What's in the Offing?
by Zacks Equity Research
BD's (BDX) second-quarter fiscal 2021 results are likely to reflect strong year-over-year growth in revenues from assays in its Life Sciences segment.
Cerner (CERN) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Cerner's (CERN) first-quarter results are likely to reflect gains from strategic deals.
Should You Buy Zimmer Biomet (ZBH) Ahead of Earnings?
by Zacks Equity Research
Zimmer Biomet (ZBH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
McKesson (MCK) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
McKesson's (MCK) fiscal fourth-quarter results are likely to reflect solid show by U.S. Pharmaceutical and Specialty Solutions segment.
AmerisourceBergen (ABC) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal second-quarter results are likely to reflect solid performance at Pharmaceutical Distribution and Other units.
Invitae (NVTA) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Invitae's (NVTA) first-quarter results are likely to reflect strength in genetic testing.
Zimmer Biomet (ZBH) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Zimmer Biomet's (ZBH) first-quarter 2021 revenues are likely to have been adversely impacted due to pandemic-led lower elective procedure volumes.
PerkinElmer (PKI) to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
PerkinElmer's (PKI) first-quarter results are likely to reflect strong performance at Diagnostics segment.
DaVita (DVA) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Solid performance by net dialysis and the related lab patient service segment are likely to have aided DaVita's (DVA) top line in the first quarter.
Baxter (BAX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Baxter's (BAX) first-quarter results are likely to reflect growth in its Acute Therapies business.
ABIOMED (ABMD) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Strong momentum of ABIOMED's (ABMD) Impella product line, both in Europe and Japan, is expected to have continued in the fiscal fourth quarter as well.
DexCom (DXCM) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) first-quarter results are likely to reflect rising global awareness of its real-time CGM.
Ecolab (ECL) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Ecolab's (ECL) first-quarter results are likely to reflect strength in the Global Healthcare and Life Sciences segment.
Orthopedic Space Gains Momentum in 2021: 5 Stocks in Focus
by Debanjana Dey
Here are five orthopedic device stocks, Integra (IART), Conformis (CFMS), SeaSpine (SPNE), Zimmer Biomet (ZBH), Orthofix (OFIX), which are expected to continue their run over the next few months.
Stryker (SYK) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) first-quarter results are likely to reflect strong segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine.